Get the Stockscreener App
3.52
0.86%
0.03
After Hours:
3.49
-0.03
-0.85%
Macrogenics Inc stock is traded at $3.52, with a volume of 647.96K.
It is up +0.86% in the last 24 hours and up +17.33% over the past month.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
See More
Previous Close:
$3.49
Open:
$3.51
24h Volume:
647.96K
Relative Volume:
0.60
Market Cap:
$223.73M
Revenue:
$149.50M
Net Income/Loss:
$-74.62M
P/E Ratio:
-2.9737
EPS:
-1.1837
Net Cash Flow:
$-82.95M
1W Performance:
+2.03%
1M Performance:
+17.33%
6M Performance:
+108.28%
1Y Performance:
+179.37%
1-Day Range:
$3.495
$3.715
1-Week Range:
$3.30
$3.88
52-Week Range:
$1.10
$3.88
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.52 | 221.82M | 149.50M | -74.62M | -82.95M | -1.1837 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | B. Riley Securities | Neutral → Buy |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
Recap Report: What is the next catalyst for MacroGenics IncQuarterly Profit Report & AI Enhanced Trading Alerts - baoquankhu1.vn
MacroGenics (MGNX) price target increased by 11.11% to 4.08 - MSN
Sentiment Review: Whats the profit margin of MacroGenics Inc2026 Momentum Check & Real-Time Price Movement Reports - baoquankhu1.vn
B Riley Securities upgrades MacroGenics (MGNX) - MSN
MacroGenics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley Securities | MGNX Stock News - GuruFocus
Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley - GuruFocus
Macrogenics Inc Stock Historical Valuations | HAM:M55 - GuruFocus
Macrogenics Inc Stock Intrinsic Values | HAM:M55 - GuruFocus
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble (MGNX) - Seeking Alpha
B.Riley upgrades MacroGenics stock rating on ADAM9 ADC potential By Investing.com - Investing.com South Africa
B.Riley upgrades MacroGenics stock rating on ADAM9 ADC potential - Investing.com
B. Riley Upgrades MacroGenics to Buy From Neutral, Triples Price Target to $9 From $3 - marketscreener.com
MacroGenics gains removal of FDA partial hold on lead program - MSN
MacroGenics gains removal of FDA partial hold (MGNX:NASDAQ) - Seeking Alpha
MacroGenics says FDA removes partial clinical hold on Phase 2 LINNET study - TipRanks
FDA Lifts Partial Clinical Hold on MacroGenics’ LINNET Study for Lorigerlimab in Gynecologic Cancers, Enrollment to Resume - Minichart
MacroGenics resumes enrollment in lorigerlimab cancer study By Investing.com - Investing.com Canada
FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study - Bitget
MacroGenics resumes enrollment in lorigerlimab cancer study - Investing.com
FDA Lifts Partial Hold on MacroGenics' (MGNX) LINNET Study - GuruFocus
MacroGenics Resumes LINNET Trial After FDA Hold Lifted - TipRanks
FDA Lifts Partial Clinical Hold on MacroGenics' LINNET Study; Enrollment to Resume - TradingView — Track All Markets
FDA lifts hold on MacroGenics (NASDAQ: MGNX) LINNET gynecologic cancer trial - Stock Titan
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study - The Manila Times
MacroGenics can enroll new cancer patients after FDA lifts study hold - Stock Titan
[DEF 14A] MACROGENICS INC Definitive Proxy Statement - Stock Titan
MacroGenics: Balancing Regulatory Setbacks with Pipeline Promise () - aktiencheck.de
Dip Buying: Can MacroGenics Inc be the next market leader2026 Risk Factors & Short-Term High Return Ideas - baoquankhu1.vn
Volatility Watch: What is the next catalyst for MacroGenics IncWeekly Stock Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
Medtronic Outperforms MacroGenics in Financial Comparison - National Today
MGNX Earnings History & Surprises | EPS & Revenue Results | MACROGENICS INC (NASDAQ:MGNX) - ChartMill
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Brokerages - Defense World
Retail Trends: Can MacroGenics Inc disrupt its industryPortfolio Value Report & Smart Money Movement Alerts - baoquankhu1.vn
Investment Report: Can MacroGenics Inc expand its profit margins2026 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
Vanguard reports 0 shares in MacroGenics (NASDAQ: MGNX) - Stock Titan
Aug Drivers: How does MacroGenics Inc compare to its peersMarket Activity Recap & Short-Term Swing Trade Alerts - baoquankhu1.vn
MacroGenics Secures Financial Runway Ahead of Pivotal Clinical Milestones () - aktiencheck.de
Treasury Yields: Can MacroGenics Inc disrupt its industry2026 AllTime Highs & Verified High Yield Trade Plans - baoquankhu1.vn
Patterns Watch: What is the next catalyst for MacroGenics IncCEO Change & Fast Exit Strategy with Risk Control - baoquankhu1.vn
VIX Spike: Can MacroGenics Inc be the next market leaderTrade Entry Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn
MacroGenics (NASDAQ:MGNX) Share Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Why is MacroGenics stock sinking Tuesday? - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
Sentiment Review: Will MacroGenics Inc outperform the market in YEAR2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Bull Run: Is MacroGenics Inc attractive for institutional investorsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com Nigeria
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):